.jpg)
12 hours ago
1
Article content
DENVER — Valcadia Healthcare Partners LLC (“Valcadia”) a leading healthcare investment banking and M&A advisory firm, announced today that it has advised Carolina Urologic Cancer Center (“CURC”), the premier urologic clinical research site specializing in genitourinary oncology, in its acquisition by The START Center for Cancer Research, a global leader in early-phase oncology clinical trials. The transaction closed in April 2025 and represents Valcadia’s fourth completed outsourced pharma services transaction, a milestone which reflects the firm’s leadership in advising health sciences entrepreneurs and business owners.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
Founded in 1998 by Neal Shore, MD, FACS, CURC has conducted nearly 500 clinical trials, making it the top urologic oncology site worldwide by both volume and quality. With deep expertise in early phase as well as late phase trials, CURC brings unparalleled leadership and scientific insight to START’s global research portfolio. With the integration of CURC’s specialized trial capabilities and expertise and to further strengthen its leadership in GU oncology research, START has established a dedicated Center of Excellence (COE) focused on delivering a comprehensive trial solution for urological cancers.
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
“Joining START’s global site network marks an exciting new chapter for CURC,” said Dr. Neal Shore, Founder and Medical Director of CURC. “START is the leader in early phase oncology trials, and we share a mission to bring the hope of clinical trials to patients worldwide. I am honored to lead START’s GU Oncology growth as well as their commitment to radiopharmaceutical trial expansion.”
Article content
“Valcadia Healthcare Partners was essential in helping CURC identify the right strategic partner,” added Dr. Shore. “I strongly recommend Valcadia as they displayed unwavering professionalism, insight and diligence in guiding us through this successful transaction.”
Article content
“We are honored to have advised CURC through this pivotal partnership,” said Ethan Goodson, Founder and Managing Partner at Valcadia Healthcare Partners. “Dr. Shore and the entire CURC team have built a leading community-based urologic oncology research practice grounded in clinical excellence and strengthened by a mission-driven culture that permeates the entire organization. We are proud to have supported them in securing a partner that will preserve and build upon that identity, and we look forward to following their continued growth and success.”
Article content
Bass, Berry & Sims PLC provided legal counsel to CURC in connection with the transaction, and ReedSmith LLP provided legal counsel to START.
Article content
About Carolina Urologic Research Center
Article content
Carolina Urologic Research Center (CURC), now known as START Carolinas, has been recognized both nationally and internationally as one of the most progressive and respected clinical research sites in the United States. CURC employs a highly skilled group of healthcare professionals, including 6 board-certified urologists and 22 full-time research staff. Over the past 25 years, CURC has participated in approximately 500 national and international clinical research trials for patients with various urologic conditions. Learn more at https:// https://startresearch.com/start-carolinas For more information please visit www.valcadiahealthcarepartners.com.
Article content
Valcadia Healthcare Partners LLC, 66 S. Logan Street, Denver, CO 80209
Article content
Article content
Article content
Article content
View source version on businesswire.com:
Article content
Article content
Article content
Contacts
Article content
Article content
Article content
English (US)